CTKB
Cytek Biosciences Inc
NASDAQ: CTKB · HEALTHCARE · MEDICAL DEVICES
$4.56
+2.70% today
Updated 2026-04-30
Market cap
$565.62M
P/E ratio
—
P/S ratio
2.81x
EPS (TTM)
$-0.52
Dividend yield
—
52W range
$2 – $6
Volume
0.7M
Cytek Biosciences Inc (CTKB) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $57.88M | $92.84M | $127.95M | $164.04M | $193.01M | $200.45M | $201.49M |
| Revenue growth (YoY) | — | +60.4% | +37.8% | +28.2% | +17.7% | +3.9% | +0.5% |
| Cost of revenue | $29.21M | $41.13M | $48.81M | $63.06M | $83.59M | $89.35M | $97.03M |
| Gross profit | $28.67M | $51.71M | $79.14M | $100.97M | $109.43M | $111.11M | $104.46M |
| Gross margin | 49.5% | 55.7% | 61.9% | 61.6% | 56.7% | 55.4% | 51.8% |
| R&D | $8.93M | $13.69M | $24.44M | $34.86M | $44.15M | $39.40M | $36.47M |
| SG&A | $6.74M | $9.37M | $20.84M | $34.69M | $43.97M | $43.11M | $58.94M |
| Operating income | $-17.26M | $13.66M | $9.16M | $-1.80M | $-27.84M | $-20.52M | $-40.38M |
| Operating margin | -29.8% | 14.7% | 7.2% | -1.1% | -14.4% | -10.2% | -20.0% |
| EBITDA | $-15.98M | $15.37M | $8.92M | $9.49M | $-4.41M | $-10.03M | $-17.39M |
| EBITDA margin | -27.6% | 16.6% | 7.0% | 5.8% | -2.3% | -5.0% | -8.6% |
| EBIT | $-16.29M | $14.76M | $7.68M | $3.83M | $-13.64M | $-20.52M | $-29.37M |
| Interest expense | $1000.00 | $333000.00 | $1.74M | $2.57M | $2.07M | $5.24M | $474000.00 |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-16.83M | $19.41M | $3.00M | $2.58M | $-12.15M | $-6.02M | $-66.54M |
| Net income growth (YoY) | — | +215.4% | -84.5% | -14.2% | -571.6% | +50.4% | -1005.3% |
| Profit margin | -29.1% | 20.9% | 2.3% | 1.6% | -6.3% | -3.0% | -33.0% |